1. The effects of vasopressin on the metabolism of starved rats were investigated by using a constant-infusion regimen (50pmol/kg body wt. per min, after an initial loading dose of 150pmol/kg body wt.). 2. Blood ketone bodies decreased by 50% in 10min, and this was accompanied by a 60% decrease in the plasma non-esterified fatty acids. 3. Blood glucose increased by 0.9 mm within 5 min and decreased to control values over the 40min infusion. Small increases in lactate and pyruvate also occurred. 4. Plasma insulin was not increased by vasopressin infusion. 5. The net decrease in blood ketone bodies caused by vasopressin was similar when somatostatin was infused simultaneously (1 nmol/kg body wt. per min). 6. Hepatic ketone bodies were significantly decreased by vasopressin, as was the 3-hydroxybutyrate/acetoacetate ratio. A small increase in the hepatic concentration of several glycolytic intermediates also occurred. 7. Vasopressin did not decrease the ketonaemia produced by infusions of octanoate or long-chain triacylglycerol in rats that had been pre-treated with the anti-lipolytic agent 3,5-dimethylpyrazole. 8. In comparison with vasopressin, the infusion of adrenaline or glucose had much smaller effects in decreasing the ketonaemia of starvation, despite the 4-fold increase in plasma insulin, at 10min, with the glucose infusion. 9. The primary metabolic effect of vasopressin in the starved rat appears to be that of decreased supply of non-esterified fatty acid to the liver. It is suggested that vasopressin has a direct anti-lipolytic effect in adipose tissue.
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Hormones of the posterior pituitary (vasopressin, oxytocin), in addition to their accepted physiological functions, exert potent effects on hepatic metabolism (Hems, 1979) . A well-established effect of vasopressin is the stimulation of hepatic glycogenolysis (Hems et al., 1978a; Hue et al., 1981) , secondary to the activation of glycogen phosphorylase a (Hems et al., 1975; Kirk et al., 1979; Hers & Van Schaftingen, 1982) . Unlike glucagon, which also has the above property, vasopressin stimulates hepatic glycolysis Hue et al., 1981) . This has been attributed to activation of pyruvate dehydrogenase (Hems et al., 1978b) and phosphofructokinase, the latter as a result of the accumulation of fructose 2,6-bisphosphate, a potent activator of this enzyme (Hers & Van Schaftingen, 1982) . In addition, vasopressin has several unique effects on hepatic lipid metabolism (see Sugden & Williamson, 1981) . These include the inhibition of ketogenesis from oleate, stimulation of the esteri- fication and oxidation of this fatty acid Sugden et al., 1980) and accelerated turnover of phosphatidylinositol (Kirk et al., 1979 (Kirk et al., , 1981 . Most of these effects are associated with the redistribution of Ca2+ within the liver cell [cyclic AMP(and/or cyclic! GMP)-independentl. The possible clinical implications of these findings in relation to the stressed fed state have been discussed Sugden & Williamson, 1981) .
In contrast with the range of effects seen in the fed (glycogen-replete) liver, the only well-established effect of vasopressin in vitro in the starved liver is the stimulation of gluconeogenesis (Hems & Whitton, 1973; Siess et al., 1978; Whitton et al., 1978) . Lipid metabolism, however, appears to be unaffected by vasopressin. Ketogenesis in vitro from endogenous (Siess et al., 1978) or exogenous fatty acid is not inhibited, esterification of oleate is similarly unaffected , and pyruvate dehydrogenase is not activated (Denton et al., 1981) , nor is phosphofructokinase (Hue et al., 1981 Sugden & Williamson, 1981) . However, vasopressin may have effects on hepatic metabolism in the whole animal which are unlikely to be seen under the conditions of restricted substrate supply used in hepatocyte studies. By analogy, adrenaline appears to have either no (Siess et al., 1978) or minor (Burrin et al., 1982) stimulatory effects on ketogenesis from starved rats, yet in vivo it decreases the ketonaemia of starvation, apparently by a hepatic mechanism (Sugden et al., 1982) .
The effects of vasopressin in vivo in the fed rat have been investigated by Hems et al. (1975) , using a single intraperitoneal dose of the hormone. They found that a substantial increase in blood glucose concentration, with a subsequent increase in insulin concentration, were the predominant effects. A more recent study, also using fed rats, showed similar results (Triscari & Sullivan, 1981) . The above approach to investigating the action of vasopressin in vivo has some shortcomings, including the use of single large doses of a hormone which has a short half-life (Janaky et al., 1982) . The aim of the present study was to examine the metabolic effects of vasopressin in the starved rat by using constant infusions of the hormone, and, in particular, to see whether its lack of effect on hepatic ketogenesis in the starved state in vitro also applies in vivo. (Williamson et al., 1962) ; glucose (Slein, 1963) ; L-lactate and pyruvate (Hohorst et al., 1959) ; glucose 6-phosphate and ATP (Lamprecht & Trautschold, 1963) ; ADP and AMP (Adam, 1963) ; glycerol 3-phosphate (Hohorst, 1963a) ; phosphoenolpyruvate, 2-phosphoglycerate and 3-phosphoglycerate (Czok & Eckert, 1963) ; citrate (Dagley, 1963) ; L-malate (Hohorst, 1963b) ; L-alanine (Williamson et al., 1967b) ; L-glutamate (Bernt & Bergmeyer, 1963) ; L-aspartate (Pfleiderer, 1963) ; and 2-oxoglutarate (Bergmeyer & Bernt, 1963 (Little et al., 1966; Errington & Rocha E Silva, 1972; Janaky et al., 1982) , and the results from other studies using similar infusion protocols where plasma vasopressin concentrations were monitored (Morton et al., 1982) . The plasma vasopressin concentration in the present study was estimated to be in the range 1-5 nm.
Materials and methods
The infusion of vasopressin into starved anaesthetized rats resulted in an immediate decrease in the blood ketone-body concentration (1.07 mm in 10min; Fig. 1 ). This change was accompanied by a significant increase in glucose (0.91mm at 5min), which returned to near pre-infusion values over 40min. Increases in lactate and pyruvate were also observed, amounting to a 2-fold increase in 10min. The lactate/pyruvate ratio was unchanged. Salineinfused control rats showed only a small and non-significant increase in glucose and lactate during the infusion period (Fig. 1) .
The increase in blood glucose is consistent with a stimulation of hepatic gluconeogenesis (Hems & Whitton, 1973; Siess et al., 1978; Whitton et al., 1978) , with a possible contribution from residual hepatic glycogen. Possible explanations for the decreased ketonaemia after infusion of vasopressin include: (a) inhibition of hepatic ketogenesis, despite its lack of effect in the starved state in vitro (Siess et al., 1978; Williamson et al., 1980) ; (b) increased peripheral utilization of ketone bodies; (c) decreased fatty acid supply to the liver, owing to either direct effects of vasopressin (vasoconstriction or inhibition of lipolysis) or secondary effects such as the release of insulin in response to the transient increase in (50pmol/kg body wt. per min after an initial bolus of l50pmol/kg body wt.) or saline (0.15M-NaCl), and metabolite concentrations were measured at the times indicated. The results are shown as means + S.E.M. for six vasopressin infusions (-) and six saline infusions (0). Significant differences between means were assessed by using Student's t test: *P < 0.05; **P < 0.01; ***P < 0.001.
blood glucose. However, plasma insulin concentrations at 40min were not significantly different [14 + 4 (6) and 22+2 (5) 10min after starting the vasopressin infusion. There was no significant change in the hepatic concentration of glucose after the infusion of vasopressin, but there were significant increases in the concentrations of pyruvate, 3-phosphoglycerate and 2-oxoglutarate, as well as small increases in several other glycolytic intermediates (Table 1 ). The total liver ketone bodies were decreased by 55%. In addition, the mitochondrial redox state was more oxidized, as shown by the decreased 3-hydroxybutyrate/acetoacetate ratio ( Table 1 ). The changes in blood metabolite concentrations in these rats showed similar results to those in Fig. 1 . In these rats, however, the 3-hydroxybutyrate/acetoacetate ratio was significantly lowered by vasopressin treatment, reflecting the changes seen in the liver (Table 2 ).
An important finding was that, 10min after starting the vasopressin infusion, plasma non-esterified fatty acids had decreased by nearly 60% (Table  2) . Unlike the effects of vasopressin administration in fed rats (Hems et al., 1975; Triscari & Sullivan, 1981) , this decrease was not accompanied by any increase in plasma insulin concentrations (Table 2) . Plasma insulin and non-esterified fatty acid concentrations at 40 min were also low in vasopressin-infused rats (results not shown). The effect of vasopressin, to decrease rapidly non-esterified fatty acid supply to the liver, would explain several changes seen in the concentrations of liver and blood metabolites. In the starved liver, reducing equivalents from the mitochondrial oxidation of fatty acid are moved to the cytosol to support gluconeogenesis, while a proportion of acetyl-CoA is diverted into ketogenesis. In the face of decreased supply of non-esterified fatty acid to the liver, and the increased energy demands of stimulated gluconeogenesis, more acetyl-CoA would be oxidized in the tricarboxylic acid cycle to provide the necessary reducing equivalents and ATP, with less carbon diverted to ketogenesis. The decreased supply of oxidizable substrate to the liver in the presence of vasopressin would also explain the more oxidized hepatic redox couples. In the cytosol, this would tend to decrease flux through glyceraldehyde 3-phosphate dehydrogenase in the direction of gluconeogenesis and would explain the accumulation of glycolytic intermediates below this point, and the decline in blood glucose concentrations after the initial increase (see Fig. 1 ).
Effect of vasopressin on the metabolism of infused lipid A model that has been used to study the aspects of hepatic ketogenesis in vivo, independent of endogenous substrate supply, incorporates the administration of an anti-lipolytic agent (Gerritsen & Dulin, 1965) , followed by the infusion of either short- (Williamson et al., 1974) , medium- (McGarry & Foster, 1971) or long-chain fatty acids (as triacylglycerol; Axelrod et al., 1979a) . With this approach, rats were first treated with 3,5-dimethylpyrazole and then infused with either octanoate or long-chain triacylglycerol (Intralipid), the latter in the presence of heparin to stimulate lipoprotein lipase.
In rats treated with 3,5-dimethylpyrazole alone, blood ketone bodies decreased within 40min to 0.4mM and only increased slightly to 0.6mM over the infusion period. Infusion of octanoate together with 3,5-dimethylpyrazole resulted in blood ketonebody concentrations similar to those seen in starvation (Fig. 2a) . Vasopressin, however, caused no inhibition of the ketonaemia generated by this treatment. In fact, a small but significant increase in & Foster, 1971) , neither does it require the carnitine acyltransferase system for transport into the mitochondrial matrix (see Williamson, 1979) . The effects of vasopressin were therefore examined when ketonaemia was supported by long-chain fatty acids provided by infusing long-chain triacylglycerol. To achieve similar ketone-body concentrations, within 10min, to those seen in starvation or with octanoate infusion, it was necessary to use infusion rates of long-chain triacylglycerol (see the Materials and methods section) which precluded reaching a steady state in short-term infusions. Under these conditions, vasopressin actually caused a significant increase in ketonaemia during the first 10min (Fig.  2b) .
These results with infusion of octanoate and long-chain triacylglycerol suggest that in the presence of ample precursor supply to the liver vasopressin is unable to exert its anti-ketogenic effect, and therefore its site of action is likely to be extrahepatic. However, the possibility that the anti-lipolytic agent or the infused fatty acid have effects in liver that mask or abolish those of vasopressin cannot be excluded.
Effects ofsimultaneous infusion ofsomatostatin and vasopressin
To verify that the effects seen with vasopressin
were not secondary to stimulation of insulin release, rats were first pre-infused with somatostatin to inhibit insulin secretion, as described by Nosadini et al. (1980) , and then simultaneously infused with vasopressin and somatostatin. The results of the pre-infusion and the first 10min of vasopressin infusion are shown in Table 3 . Ketone-body concentrations decreased by 0.75 + 0.13 (5) mm in 10min, compared with 1.07mM ( Fig. 1) and 0.96mm (Table 1) in the absence of somatostatin. However, the ketone-body concentration in rats receiving somatostatin alone increased by 0.32 + 0.08 (5)mM between 10 and 20min. Therefore there was no net difference in the effect of vasopressin on blood ketone-body concentrations in the presence of somatostatin. As expected, plasma insulin concentrations at 10 and 20min (first 10min of vasopressin infusion) were very low (range 0-7munits/l) for rats infused with either somatostatin or somatostatin plus vasopressin. During this same period, the concentration of plasma nonesterified fatty acids increased slightly in the somatostatin-infused rats, and decreased by 48% in those receiving both somatostatin and vasopressin (Table  3) .
Effect of adrenaline and glucose infusions on blood metabolite concentrations It has been shown that the subcutaneous injection of adrenaline decreases the ketonaemia of starvation (Sugden et al., 1982) . This effect appears related to alterations in hepatic gluconeogenesis and was shown to be independent of fatty acid supply to the liver. Adrenaline provides a useful comparison in Table 2 . Effect ofvasopressin infusion on blood metabolite concentrations in 24 h-starved rats The rats were those used in the freeze-clamping experiment (see Table 1 and text for details). Results are given as means +S.E.M. for seven saline and eight vasopressin infusions. The change at 1Omin was calculated from data for individual rats. **P < 0.0 1; ***P < 0.00 1.
Time ( Sugden & Williamson, 1981) . In addition, both vasopressin and adrenaline have powerful pressor effects (see below). Blood glucose and lactate increased more markedly in response to adrenaline than with vasopressin (Fig. 3) . Pyruvate increased in parallel to lactate (results not shown). Although the ketonebody concentration decreased after adrenaline administration, the initial rate of change was only 23% of that seen with vasopressin (0.25mM/lOmin, cf. 1.07mM/lOmin). However, this rate of decrease with adrenaline would, if sustained, be sufficient to account for the decrease of ketonaemia (0.6mM) reported by Sugden et al. (1982) to occur after 60min. Adrenaline tended to decrease the plasma non-esterified fatty acid concentration (results not shown), though the change was not significant, which is unexpected in light of the reported lipolytic action of catecholamines (see Alberti et al., 1978) . It is possible that acute infusion of adrenaline may actually inhibit lipolysis by a mechanism involving the a-receptor. However, although a-agonists inhibit lipolysis in adipocytes from various species, the effect in rat adipocytes is not established (Schimmel, 1979) .
Despite the similarity in pressor response and the greater increase in blood glucose, lactate and pyruvate seen with adrenaline, vasopressin caused a much larger and more immediate decrease in ketone-body concentration, which suggests that the mechanism for vasopressin action in depressing ketonaemia is not directly related to these changes alone. Another difference between the effects of the two hormones is that the ketonaemia sustained by exogenously supplied fatty acid, either medium-or long-chain, was not reversed by vasopressin, yet it was by adrenaline (Sugden et al., 1982) . It is therefore reasonable to conclude that the two hormones lower blood ketone-body concentrations by different mechanisms.
Administration of vasopressin was accompanied by an increase in blood glucose (Fig. 1) . To test whether such an increase might be sufficient to elicit the response seen with vasopressin, glucose was infused at a rate of 200,umol/kg body wt. per min into starved rats for 4min and at 20,umol/kg body wt. per min thereafter. The rise in blood glucose (2.2 mM) after the glucose infusion caused the ketone-body concentration to decrease linearly from 5min, at an initial rate one-half of that seen with vasopressin (Fig. 3) . The plasma non-esterified fatty acid concentration decreased from 0.88 + 0.06 (5) to 0.65 + 0.05 (5)mm in the first 1Omin, and insulin concentrations increased 4-fold [11 + 2 (5) to concentration in 24 h-starved rats after infusion of medium-or long-chain lipid Starved rats were pre-treated with 3,5-dimethylpyrazole and infused with either octanoate (a) or long-chain triacylglycerol (b) as described in the Materials and methods section. The vasopressin infusion (50pmol/kg body wt. per min, after an initial bolus of 150pmol/kg body wt.) was started at 1Omin. The results are shows as means + S.E.M. for four infusions with vasopressin (U) and four saline controls (0). Significant differences between means were assessed with Student's t test. *P < 0.05. 45 + 9 (5)munits; P < 0.01 during this time. These findings are consistent with inhibition of lipolysis after insulin release, with subsequent decreased substrate supply to the liver and hence diminished ketogenesis. The important finding is that, despite the 4-fold increase in the plasma insulin concentration, glucose infusion caused a smaller decrease in the blood ketone-body and non-esterified fatty acid concentrations than did vasopressin, lending further support to the view that the latter may act directly to decrease lipolysis in adipose Table 3 . Effect ofvasopressin on blood metabolite concentrations in rats infused with somatostatin Rats were infused with somatostatin (1nmol/kg body wt.-per min) for 10min and were then infused with both vasopressin (lSOpmol/kg body wt. bolus, then 50pmol/kg body wt. per min) and somatostatin for a further 30min. The results of the preinfusion and the first 10min of the simultaneous infusion are shown and are expressed as means + S.E.M. for five rats for each treatment. The significance of differences refers to the mean change (10-20 min) in metabolite concentration between treatments for individual rats. Significant differences were assessed by using Student's t test: *P < 0.05; **P < 0.01; ***P < 0.001. (Saameli, 1968) , it is unlikely that its effects are due to a general systemic vasoconstriction. Hems et al. (1976) found that vasopressin concentrations greater than 10nM were required to cause vasoconstriction in the perfused rat liver. If this were a factor in the effects seen here, some indication of anoxia (increased lactate/pyruvate ratio in liver) might be expected. This was not seen ( (Hems, 1979) . The release of vasopressin, either appropriately or inappropriately, occurs in a range of clinical situations, including haemorrhage, diabetes, head trauma, and after the use of anti-neoplastic drugs and thiazide diuretics (see Moses et al., 1976 ). The present finding in regard to the apparent anti-lipolytic effect of vasopressin has implications in relation to the metabolic changes that occur in these states, and in particular may link the following observations in regard to sepsis. (a) Infection in starved rats produces a sharp decline in the blood ketone-body and non-esterified fatty acid concentrations (Neufeld et al., 1976; . (b) This effect is not seen in hypophysectomized rats, though it was still apparent in adrenalectomized and thyroidectomized animals (Neufeld et al., 1980) . (c) Sepsis and septic shock in monkeys and dogs gives rise to large increases in the plasma vasopressin concentrations (Wilson et al., 1981) . Although insulin and other hormones may play a role in the above effects, it is reasonable to suggest that vasopressin may be responsible, at least in part, for the metabolic disturbances seen during sepsis. The present findings may help to explain why there is often a failure to achieve raised blood ketone-body concentrations in various other disease and injury states associated with low energy intake (Smith et al.. 1975; Conyers et al., 1979; Rich & Wright, 1979 
Conclusions
The primary metabolic effect of vasopressin in the starved rat was a rapid decrease in ketonaemia, with an associated decrease in the plasma concentration of non-esterified fatty acids. As no increase in plasma insulin accompanied these changes, it is suggested that vasopressin may affect fatty acid release from adipose tissue in a manner similar to insulin and prostaglandin E2 (Hales et al., 1978; Axelrod et al., 1979b) . Oxytocin, which has close structural similarities to vasopressin, does have mild anti-lipolytic effects in vitro (Rodbell, 1964) . Furthermore, oxytocin has binding sites on the surface of rat adipocytes which appear to have an even greater affinity for vasopressin, as 1251-labelled oxytocin is more readily displaced from its binding sites by vasopressin than by oxytocin itself (Thompson et al., 1972) . It is therefore postulated that vasopressin has a direct anti-lipolytic effect on the adipocyte.
